Clinical trials: Controlled Hypertension
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5…
- Trial name
- NCT00383929
- Testing
- Candesartan cilexetil, Hydrochlorothiazide
- Where
- 132 sites in Denmark, Estonia and 9 more
- Volunteers
- 1,979 people
- Sponsor
- AstraZeneca
Hypertension
The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
This is a randomized, double-blind, double-dummy, parallel group trial employing 15 cells of a 4x4 factorial design (no placebo)to compare the hypertensive effects in patients with Stage 1 and Stage 2 hypertension of carvedilol…
- Trial name
- NCT00347360
- Testing
- lisinopril, carvedilol controlled release formulation
- Where
- 151 sites in United States
- Volunteers
- 654 people
- Sponsor
- GlaxoSmithKline
Glaucoma, Trabeculectomy
Ologen (OculusGen)-Glaucoma MMC Control in Pakistan
The purpose of this study is to compare the safety and effectiveness of the ologen (OculusGen) Biodegradable Collagen Matrix Implant and the MMC group in filtration surgery.
- Trial name
- NCT00472810
- Testing
- ologen collagen matrix in glaucoma filtering surgery, MMC in glaucoma filtering surgery
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Pro Top & Mediking Company Limited
Pulmonary Arterial Hypertension
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or…
- Trial name
- NCT05818137
- Testing
- Sotatercept
- Where
- 17 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Safety and Tolerability of NTX-101 in Korean Healthy Volunteers
A double-blinded, placebo controlled, multiple dose, randomized, single site, phase 1 clinical trial to evaluate safety, tolerability, and pharmacokinetics of NTX-101 topical eye drop in Korean healthy volunteers
- Trial name
- NCT05041543
- Testing
- NTX-101
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pinotbio, Inc.
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Open Angle Glaucoma or Ocular Hypertension
OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular…
- Trial name
- NCT05583474
- Testing
- OPC-1085EL, 0.005% Latanoprost
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Otsuka Beijing Research Institute
Glaucoma, Primary Open Angle Glaucoma
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma.
- Conditions
- Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigment Dispersion Glaucoma
- Trial name
- TES-GPS (NCT06682962)
- Testing
- Transcorneal electrical stimulation (TES) with the OkuStim 2 System
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Okuvision GmbH
Primary Hypertension
Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension
The purpose of this study is to assess the safety and efficacy of renal denervation with sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension in China.
- Trial name
- NCT03511313
- Testing
- Renal denervation, Renal angiography
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Synaptic Medical Corporation
Hypertension
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
- Trial name
- NCT06857955
- Testing
- Saline, QCZ484
- Where
- 72 sites in United States, Japan and 1 more
- Volunteers
- 396 people
- Sponsor
- Novartis Pharmaceuticals
Diastolic Dysfunction, Hypertension
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
Patients who have had high blood pressure for a long time may have diastolic dysfunction. Diastolic Dysfunction is when your heart has difficulty filling and emptying, and relaxing adequately.
- Trial name
- NCT00170924
- Testing
- Valsartan
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Novartis
Hypertension
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in patients with essential hypertension.
- Trial name
- NCT00446524
- Testing
- Valsartan + Amlodipine besilate
- Where
- Japan
- Volunteers
- 403 people
- Sponsor
- Novartis
Hypertension, Acute Severe Hypertension
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.
- Conditions
- Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
- Trial name
- KARDINAL-ASH (NCT07511361)
- Testing
- Tonlamarsen
- Where
- 13 sites in United States
- Volunteers
- 140 people
- Sponsor
- Kardigan, Inc.
Pulmonary Hypertension
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
- Trial name
- NCT00159861
- Testing
- Sildenafil citrate
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
- Trial name
- NCT00528827
- Testing
- Cardene® I.V.
- Where
- 2 sites in United States
- Sponsor
- Facet Biotech
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy.
- Trial name
- NCT05526703
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Hypercholesterolemia, Hypertension
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.
- Trial name
- NCT04659070
- Testing
- Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypertension
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
This is a randomized, comparative Phase 3 trial to investigate the efficacy of fixed dose combination (FDC) of bisoprolol and amlodipine in hypertensive subjects (superiority of FDC over monotherapies).
- Trial name
- NCT01977794
- Testing
- Bisoprolol/Amlodipine (Bisoprolol failed group), Bisoprolol/Amlodipine (Amlodipine failed group)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Hypertension
To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension
This is a two part study. Part 1 will determine determine if administration of TC-5214 has an effect on sitting blood pressure in patients with chronic hypertension.
- Trial name
- NCT01403922
- Testing
- TC-5214
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
- Trial name
- PATENT-1 (NCT00810693)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 122 sites in United States, Argentina and 28 more
- Volunteers
- 445 people
- Sponsor
- Bayer